# OnCo record kelonia-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/kelonia-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "kelonia-therapeutics" ;
  schema:name "Kelonia Therapeutics"@en ;
  schema:description "Kelonia developed a way to create CAR T cells directly inside the body using a targeted gene delivery particle, so patients do not need their cells removed and manufactured. Its lead programme is for multiple myeloma, and Eli Lilly bought the company in the second quarter of 2026 in a deal worth up to $7 billion."@en ;
  schema:url <https://onco.cc/companies/kelonia-therapeutics/>, <https://keloniatx.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://keloniatx.com/>, <https://keloniatx.com/pipeline/>, <https://www.prnewswire.com/news-releases/lilly-to-acquire-kelonia-therapeutics-to-advance-in-vivo-car-t-cell-therapies-302747122.html>, <https://www.sec.gov/Archives/edgar/data/59478/000005947826000077/q226lillysalesandearningsp.htm>, <https://www.sec.gov/Archives/edgar/data/1925270/000192527022000002/primary_doc.xml> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/> ;
  onco:technologies <https://onco.cc/technologies/in-vivo-car-t/> ;
  onco:targets <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/cd19/> .